Brainstorm Cell Therapeutics Inc. (BCLI)

Business: Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

IPO Date: 28-Aug-2003

Chief Exec. Officer: Mr. Chaim Lebovits

Co-Founder & Independent Vice Chair of the Board: Dr. Irit Arbel DSc, Ph.D.

Listing: NASDAQ: BCLI

Country: United States

Headquarters: New York, NY

Website: https://www.brainstorm-cell.com

Market cap: $100.34 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-23.16 Mln

Cash: $18.40 Mln

Total Debt: $5.56 Mln

Insider's Holding: 22.57%

Liquidity: Low

52 Week range: $2.65 - 4.46

Shares outstanding: 36,486,200

10 Years Aggregate:

• CFO: $-112.18 Mln
• EBITDA: $-126.95 Mln
• Net Profit: $-129.47 Mln